G-protein-coupled receptor oligomerization and its potential for drug discovery

Nature Reviews Drug Discovery

Volumn 1, Issue 10, 2002, Pages 808-820

  George, Susan R ^a,b   O'Dowd, Brian F ^a,b   Lee, Samuel P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; BOMBESIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GONADORELIN RECEPTOR; LEVODOPA; MONOMER; MUSCARINIC RECEPTOR; NEUROTENSIN RECEPTOR; OPIATE ANTAGONIST; SEROTONIN 1 RECEPTOR; SUMATRIPTAN; CELL SURFACE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN;

BINDING AFFINITY; CELLULAR DISTRIBUTION; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG TARGETING; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; ANIMAL; CHEMISTRY; CLASSIFICATION; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; METHODOLOGY; PHARMACEUTICS; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DELIVERY SYSTEMS; GTP-BINDING PROTEINS; HUMANS; RECEPTORS, CELL SURFACE; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036780743     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd913     Document Type: Review

References (125)

1. Howard, A. D. et al. Orphan G protein-coupled receptors and natural ligand discovery. Trends Pharmacol. Sci. 22, 132-140 (2001).
2. Spiegel, A. M. Defects in G protein-coupled signal transduction in human disease. Annu. Rev. Physiol. 58, 143-170 (1996).
3. Rana, B. K., Shiina, T & Insel, P. A. Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 41, 593-624 (2001).
4. Bailey, W. J. et al. Patent status of therapeutically important G protein-coupled receptors. Expert Opin. Ther. Patents 11, 1861-1887 (2001).
5. Bockaert, J. & Pin, J. P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 18, 1723-1729 (1999).
6. Gether, U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 21, 90-113 (2000).
7. Heldin, C. H. Dimerization of cell surface receptors in signal transduction. Cell 80, 213-223 (1995).
8. Salahpour, A., Angers, S. & Bouvier, M. Functional significance of oligomerization of G-protein-coupled receptors. Trends Endocrinol. Metab. 11, 163-168 (2000).
9. Lee, D. K., George, S. R., Evans, J. F., Lynch, K. R. & O'Dowd, B. F. Orphan G protein-coupled receptors in the CNS. Curr. Opin. Pharmacol. 1, 31-39 (2001).
10. 3 receptor dimers and tetramers in brain and in transfected cells. J. Biol. Chem. 272, 29229-29237 (1997).
11. 1 dopamine receptor function without affecting receptor oligomerization. J. Biol. Chem. 273, 30244-30248 (1998).
12. 2 dopamine receptors exist as oligomers in the cell. Mol. Pharmacol. 58, 120-128 (2000).
13. Chidiac, P., Green, M. A., Pawagi, A, B. & Wells, J. W. Cardiac muscarinic receptors. Cooperativity as the basis for multiple states of affinity. Biochemistry 36, 7361-7379 (1997).
14. Romano, C., Yang, W. L. & O'Malley, K. L. Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J. Biol. Chem. 271, 28612-28616 (1996).
15. Bai, M., Trivedi, S. & Brown, E. M. Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells. J. Biol. Chem. 273, 23605-23610 (1998).
16. Kunishima, N, et al. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 407, 971-977 (2000).
17. 2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J. Biol. Chem. 271, 16384-16392 (1996).
18. Cvejic, S. & Devi, L. A. Dimerization of the δ-opioid receptor: implication for a role in receptor internalization. J. Biol. Chem. 272, 26959-26964 (1997).
19. B receptor activity. J. Biol. Chem. 274, 7607-7610 (1999).
20. Rocheville, M. et al. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem. 275, 7862-7869 (2000).
21. Jordan, B. A. & Devi, L. A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399, 697-700 (1999).
22. George, S. R. et al. Oligomerization of μ- and δ-opioid receptors. Generation of novel functional properties. J. Biol. Chem. 275, 26128-26135 (2000).
23. 2 vasopressin receptors. J. Biol. Chem. 275, 2381-2389 (2000).
24. Mellado, M. et al. Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J. 20, 2497-2507 (2001).
25. Casey, J. R. & Reithmeier R. A. Detergent interaction with band 3, a model polytopic membrane protein. Biochemistry 32, 1172-1179 (1993).
26. Whitfield, G. K., Jurutka, P. W., Haussler, C. A. & Haussler, M. R. Steroid hormone receptors: evolution, ligands, and molecular basis of biologic function. J. Cell. Biochem. 33 (Suppl. 32), 110-122 (1999).
27. Jahangeer, S. & Rodbell, M. The disaggregation theory of signal transduction revisited: further evidence that G proteins are multimeric and disaggregate to monomers when activated. Proc. Natl Acad. Sci. USA 90, 8782-8786 (1993).
28. Yen, K., Greene, E., Belga, F. & Rasenick, M. M. Synaptic membrane G proteins are complexed with tubulin in situ. J. Neurochem. 66, 1489-1495 (1996).
29. Limbird, L. E., Meyts, P. D. & Lefkowitz, R. J. β-Adrenergic receptors: evidence for negative cooperativity. Biochem. Biophys. Res. Commun. 64, 1160-1168 (1975).
30. Henis, Y. I. & Sokolovsky, M. Muscarinic antagonists induce different receptor conformations in rat adenohypophysis. Mol. Pharmacol. 24, 357-365 (1983).
31. 2 muscarinic receptors expressed in Chinese hamster ovary cells. J. Biol. Chem. 269, 26127-26135 (1994).
32. Mattera, R., Pitts, B. J., Entman, M. L. & Birnbaumer, L. Guanine nucleotide regulation of a mammalian myocardial muscarinic receptor system. Evidence for homo- and heterotropic cooperativity in ligand binding analyzed by computer-assisted curve fitting. J. Biol. Chem. 260, 7410-7421 (1985).
33. Boyer, J. L., Martinez-Carcamo, M., Morroy-Sanchez, J. A., Posadas, C. & Garcia-Sainz, J. A. Guanine nucleotide-induced positive cooperativity in muscarinic-cholinergic antagonist binding. Biochem. Biophys. Res. Commun. 134, 172-177 (1986).
34. 2 muscarinic receptors. Mol. Pharmacol. 39, 211-221 (1991).
35. 3H]histamine in guinea pig cerebral cortex. II. Mechanistic basis for multiple states of affinity [corrected]. Mol. Pharmacol. 43, 583-594 (1993).
36. Wreggett, K. A. & Wells, J. W. Cooperativity manifest in the binding properties of purified cardiac muscarinic receptors. J. Biol. Chem. 270, 22488-22499 (1995).
37. Chazenbalk, G. D., Kakinuma, A., Jaume, J. C., McLachlan, S. M. & Rapoport, B, Evidence for negative cooperativity among human thyrotropin receptors overexpressed in mammalian cells. Endocrinology 137, 4586-4591 (1996).
38. 2 receptor dimer formation: evidence from ligand binding. J. Biol. Chem. 276, 22621-22629 (2001).
39. 2 receptor. J. Biol. Chem. 273, 1309-1315 (1998).
40. 1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407, 94-98 (2000).
41. Hurtley S. M. & Helenius, A. Protein oligomerization in the endoplasmic reticulum. Annu. Rev. Cell Biol. 5, 277-307 (1989).
42. Brown, D. & Breton, S. Sorting proteins to their target membranes. Kidney Int. 57, 816-824 (2000).
43. 3 receptors. Mol. Pharmacol. 58, 677-683 (2000).
44. Benkirane, M., Jin, D. Y., Chun, R. F., Koup, R. A. & Jeang, K. T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by CCR5Δ32. J. Biol. Chem. 272, 30603-30606 (1997).
45. 2 receptor function. Biochemistry 37, 15773-15784 (1998).
46. 3 dopamine receptor: evidence for heterooligomenzation. Brain Res. Mol. Brain Res. 80, 63-74 (2000).
47. Okuda-Ashitaka, E. et al. Suppression of prostaglandin E receptor signaling by the variant form of EP1 subtype. J. Biol. Chem. 271, 31255-31261 (1996).
48. Osuga, Y. et al. Co-expression of defective luteinizing hormone receptor fragments partially reconstitutes ligand-induced signal generation. J. Biol. Chem. 272, 25006-25012 (1997).
49. Grosse, R., Schoneberg, T., Schultz, G. & Gudermann, T. Inhibition of gonadotropin-releasing hormone receptor signaling by expression of a splice variant of the human receptor. Mol. Endocrinol. 11, 1305-1318 (1997).
50. B receptor function. Science 283, 74-77 (1999).
51. Kaupmann, K. et al. GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature 396, 683-687 (1998).
52. White, J. H. et al. Heterodimerization is required for the formation of a functional GABA(B) receptor Nature 396, 679-682 (1998).
53. B receptors. J. Biol. Chem. 273, 26361-26367 (1998).
54. Margeta-Mitrovic, M., Jan, Y. N. & Jan, L. Y. A trafficking checkpoint controls GABA(B) receptor heterodimerization. Neuron 27, 97-106 (2000).
55. Levac, B. A., O'Dowd, B. F. & George, S. R. Oligomerization of opioid receptors: generation of novel signaling units. Curr. Opin. Pharmacol. 2, 76-81 (2002).
56. Pfeiffer, M. et al. Homo- and herterodimerization of somatostatin receptor subtypes. Inactivation of SST(3) receptor function by heterodimerization with SST(2A). J. Biol. Chem. 276, 14027-14036 (2001).
57. AbdAlla S., Lother, H., el Massiery, A, & Quitterer, U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nature Med. 7, 1003-1009 (2001).
58. Robbins, M. J. et al. GABA(B2) is essential for G-protein coupling of the GABA(B) receptor heterodimer. J. Neurosci. 21, 8043-8052 (2001).
59. Palczewski, K. et al. Crystal structure of rhodopsin: a G protein-coupled receptor Science 289, 739-745 (2000).
60. 3 muscarinic receptor dimers. J. Biol. Chem. 274, 19487-19497 (1999).
61. Lee, S. P. et al. Oligomerization of dopamine and serotonin receptors. Neuropsychopharmacology 23, S32-S40 (2000).
62. 2 receptor dimers and receptor-blocking peptides. Biochem. Biophys. Res. Commun. 227, 200-204 (1996).
63. Lemmon, M. A. et al. Glycophorin A dimerization is driven by specific interactions between transmembrane α-helices. J. Biol. Chem. 267, 7683-7689 (1992).
64. 2+ receptor: effects on cell surface expression, dimerization and signal transduction. FEBS Lett, 436, 353-356 (1998).
65. Ward, D. T. Brown, E. M. & Harris, H. W. Disulfide bonds in the extracellular calcium-polyvalent cation-sensing receptor correlate with dimer formation and its response to divalent cations in vitro. J. Biol. Chem. 273, 14476-14483 (1998).
66. Tsuji, Y. et al. Cryptic dimer interface and domain organization of the extracellular region of metabotropic glutamate receptor subtype 1. J. Biol. Chem. 275, 28144-28151 (2000).
67. 2 receptor in agonist-induced receptor dimerization. J. Biol. Chem. 274, 26113-26119 (1999).
68. Bowery, N. G. et al. International Union of Pharmacology. XXXIII. Mammalian γ-aminobutyric acid(B) receptors: structure and function. Pharmacol. Rev. 54, 247-264 (2002).
69. Pagano, A. et al. C-terminal interaction is essential for surface trafficking but not for heteromeric assembly of GABA(B) receptors. J. Neurosci. 21, 1189-1202 (2001)
70. Ng, G. Y. et al. Resistance of the dopamine D2L receptor to desensitization accompanies the up-regulation of receptors on to the surface of Sf9 cells. Endocrinology 138, 4199-4206 (1997).
71. McVey, M. et al. Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer. The human δ-opioid receptor displays constitutive oligomerization at the cell surface, which is not regulated by receptor occupancy. J. Biol. Chem. 276, 14092-14099 (2001).
72. Himeno, A., Shigematsu, K., Taguchi, T. & Niwa, M. Endothelin-1 binding to endothelin receptors in the rat anterior pituitary gland: interaction in the recognition of endothelin-1 between ETA and ETB receptors. Cell. Mol. Neurobiol. 18, 447-452 (1998).
73. Angers, S. et al. Detection of β2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc. Natl Acad. Sci. USA 97, 3684-3689 (2000).
74. Kroeger, K. M., Hanyaloglu, A. C., Seeber, R. M., Miles, L. E. & Eidne, K. A, Constitutive and agonist-dependent homo-oligomerization of the thyrotropin-releasing hormone receptor. Detection in living cells using bioluminescence resonance energy transfer J. Biol. Chem. 276, 12736-12743 (2001).
75. Rochevile, M. et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288, 154-157 (2000).
76. Cornea, A., Janovick, J. A., Maya-Nunez, G. & Conn, P. M. Gonadotropin-releasing hormone receptor micro-aggregation. Rate monitored by fluorescence resonance energy transfer. J. Biol. Chem. 276, 2153 2158 (2001).
77. 35]GTPγS binding responses. Brain Res. Mol. Brain Res. 67, 107-123 (1999).
78. Halazy S. et al. Serotonin dimers: application of the bivalent ligand approach to the design of new potent and selective 5-HT(1B/1D) agonists. J. Med. Chem. 39, 4920-4927 (1996).
79. Perez, M. et al. Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist. Bioorg. Med. Chem. Lett. 8, 675-680 (1998).
80. Yano, K., Kimura, S. & Imanishi, Y. Simultaneous activation of two different receptor systems by enkephalin/neurotensin conjugates having spacer chains of various lengths. Eur. J. Pharm. Sci. 7, 41-48 (1998).
81. Portoghese, P. S. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol. Sci. 10, 230-235 (1989).
82. Hazum, E. & Kehan, D. Gonadotropin releasing hormone activation is mediated by dimerization of occupied receptors. Biochem. Biophys. Res. Commun. 133, 449-456 (1985).
83. 2 receptors. J. Biol. Chem. 277, 18091-18097 (2002).
84. Jordan, B. A., Trapaidze, N., Gomes, I., Nivarthi, R. & Devi, L. A. Oligomerization of opioid receptors with β2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc. Natl Acad. Sci. USA 98, 343-348 (2001).
85. Tarasova, N. I., Rice, W. G. & Michejda, C. J. Inhibition of G-protein-coupled receptor function by disruption of transmembrane domain interactions. J. Biol. Chem. 274, 34911-34915 (1999).
86. Yudt, M. R. & Koide, S. Preventing estrogen receptor action with dimer-interface peptides. Steroids 66, 540-558 (2001).
87. Salim, K. et al. Oligomerization of G-protein-coupled receptors shown by selective co-immunopreciptation. J. Biol. Chem. 277, 15482-15485 (2002).
88. Pfeiffer, M. et al. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization, J. Biol. Chem. 277, 19762-19772 (2002).
89. Rodriguez-Frade, J. M. et al. The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2. Proc. Natl Acad. Sci. USA 96, 3628-3633 (1999).
90. 1 receptors form functionally interacting heteromeric complexes. Proc. Natl Acad. Sci. USA 97, 8606-8611 (2000).
91. Gouldson, P. R., Snell, C. R. & Reynolds, C. A. A new approach to docking in the β2-adrenergic receptor that exploits the domain structure of G protein-coupled receptors. J. Med. Chem. 40, 3871-3886 (1997).
92. Maggio, R., Vogel, Z. & Wess, J. Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular 'cross-talk' between G-protein-linked receptors. Proc. Natl Acad. Sci. USA 90, 3103-3107 (1993).
93. Monnot, C. et al. Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding and coupling, Reconstitution of the binding site by co-expression of two deficient mutants. J. Biol. Chem. 271, 1507-1513 (1996).
94. Baldwin, J. M. The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 12, 1693-1703 (1993).
95. Hadac, E. M. et al. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely J. Med. Chem. 42, 2105-2111 (1999).
96. 1 aderosine receptors in brain cortex. J. Neurosci. Res. 42, 813-828 (1995).
97. Vila-Coro, A. J. et al. HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. Proc. Natl Acad. Sci. USA 97, 3388-3393 (2000).
98. Vila-Coro, A. J. et al. The chemokine SDF-1α triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J. 13, 1699-1710 (1999).
99. 1 receptor. Eur J. Pharmacol. 267, 7-19 (1994).
100. Fukushima, Y. et al. Oligomer formation of histamine H2 receptors expressed in Sf9 and COS7 cells. FEBS Lett. 409, 283-286(1997).
101. Nguyen, T. et al. Discovery of a novel member of the histamine receptor family. Mol. Pharmacol. 59, 427-433 (2001).
102. Indrapichate, K. et al. Biological actions of monoclonal luteinizing hormone/human chorionic gonadotropin receptor antibodies. Biol. Reprod. 46, 265-278 (1992).
103. Ayoub, M. A. et al. Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J. Biol. Chem. 277, 21522-21528 (2002).
104. Ng, G. Y. et al. Human serotonin 1B receptor expression in Sf9 cells: phosphorylation, palmitoylation, and adenylyl cyclase inhibition. Biochemistry 32, 11727-11733 (1993).
105. Abe, J., Suzuki, H., Notoya, M., Yamamoto, T. & Hirose, S. Ig-hepta, a novel member of the G protein-coupled hepta-helical receptor (GPCR) family that has immunoglobulin-like repeats in a long N-terminal extracellular domain and defines a new subfamily of GPCRs. J. Biol. Chem. 274, 19957-19964 (1999).
106. 5 dimerization. Mol. Pharmacol. 59, 46-53 (2001).
107. Overton, M. C. & Blumer, K. J. G-protein-coupled receptors function as oligomers in vivo. Curr. Biol. 10, 341-344 (2000).
108. Yesilaltay, A. & Jenness, D. D. Homo-oligomeric complexes of the yeast α-factor pheromone receptor are functional units of endocytosis. Mol. Biol. Cell 11, 2873-2884 (2000).
109. 1D . receptors form homodimers when expressed alone and heterodimers when co-expressed. FEBS Lett. 456, 63-67 (1999).
110. 1 receptors assemble into functionally interacting complexes. J. Biol. Chem. 276, 18345-18351 (2001).
111. Yoshioka, K., Saitoh, O. & Nakata, H. Heteromeric association creates a P2Y-like adenosine receptor. Proc. Natl Acad. Sci. USA 98, 7617-7622 (2001).
112. 1 receptor antagonist. J. Biol. Chem. 276, 39721-39726 (2001).
113. 3 dopamine receptor heterodimers exhibit unique functional properties. J. Biol. Chem. 276, 30308-30314 (2001).
114. Jones, K. A. et al. GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature 396, 674-679 (1998).
115. Maggio, R. et al. G protein-linked receptors: pharmacological evidence for the formation of heterodimers. J. Pharmacol. Exp. Ther. 291, 251-257 (1999).
116. Nelson, G. et al. An amino-acid taste receptor. Nature 416, 199-202 (2002).
117. Nelson, G. et al. Mammalian sweet taste receptors. Cell 106, 381-390 (2001).
118. 1D receptor subtypes. Bioorg. Med. Chem. Lett. 8, 1407-1412 (1998).
119. 3 adenosine receptor agonists. J. Biol. Chem. 275, 30272-30279 (2000).
120. Carrithers, M. D. & Lerner, M. R. Synthesis and characterization of bivalent peptide ligands targeted to G-protein-coupled receptors. Chem. Biol. 3, 537-542 (1996).
121. 3 receptor subtypes. Arzneimittelforschung 45, 449-455 (1995).
122. Portoghese, P. S. From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. J. Med. Chem. 44, 2259-2269 (2001).
123. Bolognesi, M. L. et al. Opioid antagonist activity of naltrexone-derived bivalent ligands: importance of a properly oriented molecular scaffold to guide 'address' recognition at κ opioid receptors. J. Med. Chem. 39, 1816-1822 (1996).
124. Portoghese, P. S. The bivalent ligand approach in the design of highly selective opioid receptor antagonists. NIDA Res. Monogr. 96, 3-20 (1990).
125. Lambrecht, G. et al. The novel heteromeric bivalent ligand SB9 potently antagonizes P2Y(1) receptor-mediated responses. J. Auton. Nerv. Syst. 81, 171-177 (2000)